Galderma R&D $GALD.SW
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Nemolizumab NCT04204616 |
P3 | Active, not recruiting | Prurigo Nodularis | 500 | 2026-10-26 (+51 mo) |
| CPUO NCT07074977 |
P2 | Active, not recruiting | Chronic Pruritus of Unknown Origin | 50 | 2026-12 (+3 mo) |
| AKLIEF NCT07186413 |
P3 | Active, not recruiting | Acne Vulgaris | 561 | 2026-12-31 |
| Nemolizumab 30 mg NCT07762833 |
P3 | Recruiting | Atopic Dermatitis | 240 | 2027-10-28 |
| Nemolizumab NCT07047690 |
P2 | Recruiting | Systemic Sclerosis | 162 | 2028-05-28 (+22 mo) |
| NemoBaby NCT07660835 |
P2 | Recruiting | Moderate-to-Severe Atopic Dermatitis | 35 | 2028-07-15 |